Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Sinha

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
JACC. Cardiooncology|June 17, 2026
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin AmyloidosisDaniel P Judge, Alan X Ji, Isabella A Graef, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifsZhaozhong J Jia, Yanhong Wu, Wenrong Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemiaStephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifsPenglie Zhang, Liang Bao, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitorsZhaozhong J Jia, Yanhong Wu, Wenrong Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2023
Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated NeurodegenerationChitra Subramanian, Matthew W Frank, Rajaa Sukhun, et al.
British Journal of Haematology|July 6, 2016
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell diseaseDonna Oksenberg, Kobina Dufu, Mira P Patel, et al.
Journal of Cardiac Failure|April 11, 2025
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-UpAhmad Masri, Mandar Aras, Martha Grogan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitorsUma Sinha, Pei Hua Lin, Susan T Edwards, et al.
Journal of Medicinal Chemistry|August 23, 2018
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin AmyloidosisMark Miller, Arindom Pal, Wabel Albusairi, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
JACC. Cardiooncology|June 17, 2026
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin AmyloidosisDaniel P Judge, Alan X Ji, Isabella A Graef, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifsZhaozhong J Jia, Yanhong Wu, Wenrong Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemiaStephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifsPenglie Zhang, Liang Bao, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitorsZhaozhong J Jia, Yanhong Wu, Wenrong Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2023
Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated NeurodegenerationChitra Subramanian, Matthew W Frank, Rajaa Sukhun, et al.
British Journal of Haematology|July 6, 2016
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell diseaseDonna Oksenberg, Kobina Dufu, Mira P Patel, et al.
Journal of Cardiac Failure|April 11, 2025
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-UpAhmad Masri, Mandar Aras, Martha Grogan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitorsUma Sinha, Pei Hua Lin, Susan T Edwards, et al.
Journal of Medicinal Chemistry|August 23, 2018
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin AmyloidosisMark Miller, Arindom Pal, Wabel Albusairi, et al.
Pageof 8